Response and progression in recurrent malignant glioma

Kenneth R. Hess, Eric T. Wong, Kurt Jaeckle, Athanassios P. Kyritsis, Victor A. Levin, Michael D. Prados, W. K.Alfred Yung

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalNeuro-Oncology
Volume1
Issue number4
DOIs
StatePublished - Jan 1 1999

Fingerprint

Glioma
Drug Therapy
Astrocytoma
Glioblastoma
Disease-Free Survival
Regression Analysis
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Hess, K. R., Wong, E. T., Jaeckle, K., Kyritsis, A. P., Levin, V. A., Prados, M. D., & Yung, W. K. A. (1999). Response and progression in recurrent malignant glioma. Neuro-Oncology, 1(4), 282-288. https://doi.org/10.1215/15228517-1-4-282
Hess, Kenneth R. ; Wong, Eric T. ; Jaeckle, Kurt ; Kyritsis, Athanassios P. ; Levin, Victor A. ; Prados, Michael D. ; Yung, W. K.Alfred. / Response and progression in recurrent malignant glioma. In: Neuro-Oncology. 1999 ; Vol. 1, No. 4. pp. 282-288.
@article{2f9958ff999b450a97d8187abfa80203,
title = "Response and progression in recurrent malignant glioma",
abstract = "In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11{\%}) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9{\%}). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48{\%} for response and 28{\%} for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95{\%} confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.",
author = "Hess, {Kenneth R.} and Wong, {Eric T.} and Kurt Jaeckle and Kyritsis, {Athanassios P.} and Levin, {Victor A.} and Prados, {Michael D.} and Yung, {W. K.Alfred}",
year = "1999",
month = "1",
day = "1",
doi = "10.1215/15228517-1-4-282",
language = "English (US)",
volume = "1",
pages = "282--288",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

Hess, KR, Wong, ET, Jaeckle, K, Kyritsis, AP, Levin, VA, Prados, MD & Yung, WKA 1999, 'Response and progression in recurrent malignant glioma', Neuro-Oncology, vol. 1, no. 4, pp. 282-288. https://doi.org/10.1215/15228517-1-4-282

Response and progression in recurrent malignant glioma. / Hess, Kenneth R.; Wong, Eric T.; Jaeckle, Kurt; Kyritsis, Athanassios P.; Levin, Victor A.; Prados, Michael D.; Yung, W. K.Alfred.

In: Neuro-Oncology, Vol. 1, No. 4, 01.01.1999, p. 282-288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Response and progression in recurrent malignant glioma

AU - Hess, Kenneth R.

AU - Wong, Eric T.

AU - Jaeckle, Kurt

AU - Kyritsis, Athanassios P.

AU - Levin, Victor A.

AU - Prados, Michael D.

AU - Yung, W. K.Alfred

PY - 1999/1/1

Y1 - 1999/1/1

N2 - In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.

AB - In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.

UR - http://www.scopus.com/inward/record.url?scp=0033206868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033206868&partnerID=8YFLogxK

U2 - 10.1215/15228517-1-4-282

DO - 10.1215/15228517-1-4-282

M3 - Article

C2 - 11550320

AN - SCOPUS:0033206868

VL - 1

SP - 282

EP - 288

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -

Hess KR, Wong ET, Jaeckle K, Kyritsis AP, Levin VA, Prados MD et al. Response and progression in recurrent malignant glioma. Neuro-Oncology. 1999 Jan 1;1(4):282-288. https://doi.org/10.1215/15228517-1-4-282